Clevidipine
Cleviprex (clevidipine) is a small molecule pharmaceutical. Clevidipine was first approved as Cleviprex on 2008-08-01. It is used to treat hypertension in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Cleviprex
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clevidipine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CLEVIPREX | Chiesi Farmaceutici | N-022156 RX | 2008-08-01 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cleviprex | New Drug Application | 2019-12-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| C9248 | Injection, clevidipine butyrate, 1 mg |
Clinical
Clinical Trials
303 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | 1 | 2 | 8 | 40 | 23 | 73 | |
| Healthy volunteers/patients | — | 31 | — | — | 1 | 6 | 38 | ||
| Gastritis | D005756 | EFO_0000217 | K29.7 | — | 2 | 5 | 5 | 3 | 14 |
| Helicobacter pylori | D016480 | NCBITaxon_210 | B96.81 | 2 | — | 1 | 6 | — | 9 |
| Helicobacter infections | D016481 | EFO_1000961 | — | 1 | 4 | 4 | 1 | 9 | |
| Dyspepsia | D004415 | EFO_0008533 | K30 | 1 | 1 | — | 6 | 1 | 9 |
| Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | — | 6 | — | 6 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 4 | 1 | — | 5 |
| Sepsis | D018805 | A41.9 | — | — | 3 | 1 | — | 4 | |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | 2 | 1 | — | 3 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | C90.0 | 1 | 14 | 4 | — | — | 18 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 5 | 4 | — | 3 | 16 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | 1 | 5 | 4 | — | 3 | 13 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 6 | — | — | 6 |
| Lymphoma | D008223 | C85.9 | 1 | 3 | 1 | — | 1 | 6 | |
| Respiratory tract infections | D012141 | J06.9 | — | — | 1 | — | 4 | 5 | |
| Aggressive periodontitis | D010520 | EFO_0006342 | K05.2 | — | 2 | 2 | — | 2 | 4 |
| Mortality | D009026 | EFO_0004352 | — | — | 2 | — | — | 2 | |
| Intraabdominal infections | D059413 | — | — | 2 | — | — | 2 | ||
| Bronchitis | D001991 | J40 | — | — | 1 | — | 1 | 2 |
Show 18 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | 1 | 2 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | — | 1 | — | — | 1 | 2 | |
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | 2 | — | — | — | 2 |
| Idiopathic hypersomnia | D020177 | G47.11 | — | 2 | — | — | — | 2 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 1 | — | — | — | 2 |
| Virus diseases | D014777 | B34 | — | 1 | — | — | — | 1 | |
| Non-small-cell lung carcinoma | D002289 | — | 1 | — | — | — | 1 | ||
| Squamous cell neoplasms | D018307 | — | 1 | — | — | — | 1 | ||
| Plasma cell neoplasms | D054219 | — | 1 | — | — | — | 1 | ||
| Lung neoplasms | D008175 | C34.90 | — | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | 6 | — | — | — | — | 6 | ||
| Pharmacokinetics | D010599 | 4 | — | — | — | — | 4 | ||
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | C61 | 1 | — | — | — | — | 1 | |
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Neoplasm metastasis | D009362 | EFO_0009708 | 1 | — | — | — | — | 1 | |
| Oxidative stress | D018384 | EFO_1001905 | 1 | — | — | — | — | 1 | |
| Mycoses | D009181 | B35-B49 | 1 | — | — | — | — | 1 | |
| Anovulation | D000858 | 1 | — | — | — | — | 1 | ||
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | — | 1 | 1 | |
| Chemical and drug induced liver injury | D056486 | — | — | — | — | 1 | 1 | ||
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | — | — | — | 1 | 1 |
| Radiotherapy | D011878 | — | — | — | — | 1 | 1 | ||
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | — | — | — | 1 | 1 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 1 | 1 |
| Glomerulonephritis | D005921 | N05 | — | — | — | — | 1 | 1 | |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | — | — | — | 1 | 1 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CLEVIDIPINE |
| INN | clevidipine |
| Description | Clevidipine is a dihydropyridine. |
| Classification | Small molecule |
| Drug class | phenylpyridine vasodilators; tricyclic compounds |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl |
Identifiers
| PDB | — |
| CAS-ID | 167221-71-8 |
| RxCUI | 233603 |
| ChEMBL ID | CHEMBL1237132 |
| ChEBI ID | — |
| PubChem CID | 153994 |
| DrugBank | DB04920 |
| UNII ID | 19O2GP3B7Q (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Cleviprex - The Medicines Company
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 310 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23,994 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more